Clinical Practice of Emergency Department-Initiated Extracorporeal Cardiopulmonary Resuscitation for Cardiac Arrest in Adults
Guowu Xu,Jinxiang Wang,Wei Zhou,Jin Huang,Yifeng Chai,Haojun Fan,Shike Hou,Ziquan Liu,Yanqing Liu
DOI: https://doi.org/10.1097/cm9.0000000000002587
2023-01-01
Abstract:To the Editor: Cardiac arrest (CA) is one of the leading causes of adult death mortality globally. According to the latest American Heart Association reports,[1] the incidences of Emergency Medical Service-assessed adult out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA) were 140.7/100,000 and 10.2/1000, respectively. In the event CCPR fails to deliver a sustained return of spontaneous circulation (ROSC), extracorporeal cardiopulmonary resuscitation (ECPR), also known as CPR assisted by extracorporeal membrane oxygenation (ECMO), is often used as a rescue strategy for CA patients.[2] In comparison to CCPR, ECPR resulted in a higher ROSC rate (95% vs. 47%) and higher discharge survival rate (27.6% to 50% vs. 8% to 10.9%), and the proportion of discharged patients with favorable neurological performance was 2 to 4 times higher than patients only receiving CCPR. For a long time, the majority of institutional ECMO programs existed within a traditional academic center, and there are currently no specific guidelines for ECPR in the emergency department (ED) due to complexities and unpredictability of emergency CA patients’ conditions the unavailability of the ED's own ECMO specialists. To provide patients with timely rescue, we advocate emergency department-initiated cardiopulmonary resuscitation (ED ECPR) led by emergency physicians. Building an elite ED ECPR team with a minimum of skilled personnel is crucial due to the sporadic nature of CA admission, the urgency of ECPR initiation, the team members’ 24-h-a-day emergency duty, and the tacit understanding developed over time through teamwork. The ED ECPR team should include: (1) At least two emergency physicians trained in various skills, such as bedside ultrasound and puncture catheterization. In order to ensure patient safety and provide ample time for further treatment of reversible etiologies, these physicians are primarily responsible for verifying the indications and contraindications for ECPR, performing high-quality CCPR, communicating with families to obtain informed consent, performing ECMO catheterization, managing ECMO operations in the ED, and the final handover to the cardiac catheterization room or intensive care unit; (2) At least two emergency nurses, who mainly assist emergency physicians and are responsible for the preparation of ED ECPR-related instruments and items, routine patient care, monitoring, and bedside coagulation function monitoring, can assume the basic responsibility of a perfusionist after undergoing extensive training on operating the ECMO device, and are responsible for the completion of pre-primed circuits before the end of ECMO catheterization. Domestically manufactured ECMO successfully broke the monopoly of Medtronic, Maquet, and Sorin, providing the opportunity to develop ED ECPR on a larger scale. To date, there is no universal consensus on the indications and contraindications for ECPR but based on the current inclusion and exclusion criteria of various hospitals and from our own experience, we recommend the following indications for ED ECPR: (1) patients aged 18 to 75 years. (2) CA with witnesses and continuous CCPR was performed by bystanders. The time interval from CA to the initiation of continuous high-quality CCPR should not exceed 15 min. (3) Absence of ROSC, unstable hemodynamics, or presence of ROSC, but autonomic rhythm cannot be maintained after prolonged CCPR for 20 min. (4) The etiologies of CA are reversible (such as cardiogenic, pulmonary embolism, severe hypothermia, drug poisoning, trauma, acute respiratory distress syndrome, etc). (5) Organ donation. (6) Likely to receive an immediate heart transplant. (7) COVID-19 patients with severe heart failure or CA. Similarly, we recommend the following as absolute contraindications: (1) Severe neurologic disease with poor prognosis before CA. (2) Pre-existing uncontrolled intracranial bleeding or bleeding at other sites. (3) Pre-existing terminal illnesses such as metastatic malignancy and end-stage organ dysfunction. (4) Patient refuses ECPR. Meanwhile, relative contraindications should include (1) Untreated aortic dissection and aortic valve insufficiency. (2) Impossible cannulation due to severe vascular anomalies or previous surgical interventions. (3) Sepsis shock. (4) Advanced age (aged >75 years). (5) Low-flow duration in CA >60 min. The management of ED ECPR mainly consists of three stages: (a) Preparation for ED ECPR, which includes ECPR candidacy assessment, discussion with patient's family, and pre-priming of ECMO circuits, which can be fulfilled during CCPR. ECMO circuits can be pre-primed with heparinized saline or periodically back-flushed. Studies[3] have reported that primed circuits with only crystalloids remained infection-free for 14 days and could be used for up to 30 days. The recommended pre-primed fluid volume is 600 to 800 mL. (b) ED ECPR cannulation is normally performed from the femoral vein to the femoral artery during ongoing CCPR. Alternative approaches include the jugulo-femoral, femoro-subclavian, or jugulo-subclavian routes. Generally arterial 15 to 17 Fr and venous 19 to 25 Fr cannulae are utilized to provide satisfactory blood flow. Most circuits can deliver a blood flow of >4 L/min with a 15 Fr arterial return cannula. Currently, there are four main methods of ECPR cannulation: (1) The preferred technique for the majority of extracorporeal life support applications is percutaneous cannulation using a modified Seldinger technique, which offers fewer bleeding complications, risk of vascular ligation, and infection rate. (2) High success rates are achieved with ultrasound-guided cannulation, which uses ultrasound imaging to identify changes in vascular anatomy and estimate vessel size for cannula selection. (3) Surgical cannulation is the only option for failed percutaneous cannulation and is performed under direct vision following blood vessel exposure. (4) A hybrid exposure-assisted semi-Seldinger technique, whereby the target vessels are exposed, and the cannula is inserted under direct vision using the Seldinger technique. (c) Treatment and care during the ECMO maintenance phase. The initial target flow of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is 2.2–2.5 L · min–1 · m–2. Once VA-ECMO blood flow is ≥3 L · min–1 · m–2, adequate circulation has been established, and mechanical compressions should be discontinued. Continuous mixed venous oxygenation saturation >70 and mean arterial pressure (MAP) >65 mmHg are considered optimal parameters to maintain ideal flow; and serial lactate monitoring can be used as a method to achieve this goal. Prevention of thrombotic complications is critical in ECMO-supported patients. Heparin is the most-used anticoagulant agent. Heparin 100 U/kg should be intravenously administered after the insertion of the arterio-venous guidewire, and baseline values for activated clotting time in low-range heparin plasma concentrations (ACT-LR) and activated partial thermoplastic time (APTT) should be measured 3 min following heparin administration. During ECMO, low-dose intravenous heparin is continuously pumped to maintain the target range of 180 to 220 s for ACT-LR and 60 to 80 s for APTT. Extracorporeal Life Support Organization recommends a heparin infusion concentration of 20 U · kg–1 · h–1, while the standard dose in China is usually 8–10 U · kg–1 · h–1, which may be due to ethnic differences. The complications of ED ECPR can be roughly divided into organic and mechanical complications associated with patients and the ECMO device, respectively. The former mainly include bleeding, thrombosis, access site complications, acute kidney injury, neurological complications, infection, and the North–South syndrome, while the latter primarily includes complications related to emergency device replacement (such as blood leakage or air input of circuits, blood pump power failures, blood pump thrombosis, and acute thrombosis in oxygenator) and complications related to device change (such as infections related to ECMO circuits, chronic thrombosis which affects oxygenator gas exchange ability and/or coagulation disorders, and other device-related coagulation disorders). According to our experience, most patients treated with ED ECPR were transferred and treated for reversible etiologies once vital signs stabilized. In a few cases, patients were withdrawn from ECPR because their family members decided against further treatment. In those situations, the flow was gradually reduced, and ECMO was removed according to institutional protocols. The usual withdrawal criteria include the following: stable vital signs, recovery of native cardiopulmonary function, MAP >60 mmHg, ECMO oxygen volume fraction of 21%, a blood flow of 0.5 to 1.0 L/min, mixed venous oxygen saturation >65%, lactic acid <2.0 mmol/L, cardiac index (CI) >2.4 L · min–1 · m–2, and pulmonary capillary wedge pressure <18 mmHg. ED ECPR is a salvage therapy that is resource-intensive, costly, and has an uncertain prognosis. Ethical considerations and the patient's financial situation prior to ECPR should not be overlooked, especially in countries and regions where health insurance policies do not offer comprehensive coverage. Before initiating ECPR, it is necessary to get the patients’ and/or their families’ informed consent. This involves educating them about the device's implantation process, prognosis, complications of continuous device therapy, and the expected outcome (recovery or transplantation). It may be helpful to notify patients and their families of the possibility of ECMO withdrawal, thereby emotionally preparing them for an unfortunate outcome. ECPR is a bridge to recovery, increasing the clinician's time for decision-making or planning for other modalities. When a patient is in a “bridge to nowhere” situation, ECMO is not beneficial therapeutically to the patient and only delays their inevitable demise. Therefore, ECPR should be discontinued in this unfortunate situation to protect the patient since the likelihood of benefit is very low, and the risk of harm is almost certain. Conflicts of interest None.